These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29671951)

  • 1. Mineralocorticoid receptor inhibitor for long-standing central serous chorioretinopathy.
    Suzuki A; Takano Y; Ando Y; Ogawa J; Ishida M; Baba A; Imamura Y
    Acta Ophthalmol; 2018 Aug; 96(5):e662-e663. PubMed ID: 29671951
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
    Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C
    Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis.
    Kapoor KG; Wagner AL
    Ophthalmic Res; 2016; 56(1):17-22. PubMed ID: 26982318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES.
    Gergely R; Kovács I; Schneider M; Resch M; Papp A; Récsán Z; Nagy ZZ; Ecsedy M
    Retina; 2017 Jun; 37(6):1084-1091. PubMed ID: 27627749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study.
    Schwartz R; Habot-Wilner Z; Martinez MR; Nutman A; Goldenberg D; Cohen S; Shulman S; Guzner-Gur H; Loewenstein A; Goldstein M
    Acta Ophthalmol; 2017 Nov; 95(7):e610-e618. PubMed ID: 28653813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.
    Pichi F; Carrai P; Ciardella A; Behar-Cohen F; Nucci P;
    Int Ophthalmol; 2017 Oct; 37(5):1115-1125. PubMed ID: 27757733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy.
    Yang D; Eliott D
    Semin Ophthalmol; 2017; 32(1):36-42. PubMed ID: 27929707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy.
    Breukink MB; den Hollander AI; Keunen JE; Boon CJ; Hoyng CB
    Acta Ophthalmol; 2014 Sep; 92(6):e488-90. PubMed ID: 24698599
    [No Abstract]   [Full Text] [Related]  

  • 9. A new treatment approach - Eplerenone - in central serous chorioretinopathy - Case report.
    Cioboata M; Alexandrescu C; Hopinca CA; Pienaru MC; Merticariu A; Schmitzer S
    J Med Life; 2016; 9(1):92-94. PubMed ID: 27713772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bullous central serous chorioretinopathy with retinal pigment epithelial macro rip treated with eplerenone monotherapy.
    Naharwal A; Samanta R; Jayaraj S; Agrawal A
    BMJ Case Rep; 2024 Aug; 17(8):. PubMed ID: 39214585
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of diffuse retinal pigment epitheliopathies by antialdosterones or by photodynamic therapy].
    Kouassi AC; Masse H; Lebreton O; Weber M
    J Fr Ophtalmol; 2015 Jun; 38(6):e129. PubMed ID: 25976130
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR).
    Herold TR; Rist K; Priglinger SG; Ulbig MW; Wolf A
    Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):221-229. PubMed ID: 27475933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY.
    Ghadiali Q; Jung JJ; Yu S; Patel SN; Yannuzzi LA
    Retina; 2016 Mar; 36(3):611-8. PubMed ID: 26405766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPIRONOLACTONE AS A THERAPEUTIC ALTERNATIVE FOR THE BULLOUS VARIANT OF CENTRAL SEROUS CHORIORETINOPATHY.
    Ramos-Yau EC; Muñoz-Domínguez E; Contreras-Mérida SP; Valencia-Londoño LM
    Retin Cases Brief Rep; 2020; 14(4):381-385. PubMed ID: 29595560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.
    Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F
    Retina; 2013; 33(10):2096-102. PubMed ID: 23719402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy].
    Maier M; Stumpfe S; Feucht N; Strobl P; Rath V; Lohmann CP
    Ophthalmologe; 2014 Feb; 111(2):173-80. PubMed ID: 24510173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence.
    Bousquet E; Zhao M; Daruich A; Behar-Cohen F
    Exp Eye Res; 2019 Oct; 187():107754. PubMed ID: 31401003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy.
    Pociej-Marciak W; Karska-Basta I; Ozog-Baran J; Kubicka-Trzaska A; Filemonowicz-Skoczek A; Romanowska-Dixon B
    Klin Oczna; 2016 Aug; 118(1):48-54. PubMed ID: 29715409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Eplerenone treatment in chronic central serous chorioretinopathy].
    Sampo M; Soler V; Gascon P; Ho Wang Yin G; Hoffart L; Denis D; Matonti F
    J Fr Ophtalmol; 2016 Jun; 39(6):535-42. PubMed ID: 27230892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. To the editor.
    Sizmaz S; Esen E; Barman S; Demircan N
    Retina; 2014 Aug; 34(8):e19-20. PubMed ID: 25011029
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.